BMY - CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

2024-05-02 15:32:05 ET

Summary

• CytomX Therapeutics, Inc. results from phase 1a dose-escalation study, using CX-904 for the treatment of patients with EGFR expressing solid tumors, expected with Q1 2024 earnings on May 8, 2024.
• Pending positive data, plus at the discretion of partner Amgen, a phase 1b study using CX-904 targeting EGFR expressing solid tumors, expected 2nd half of 2024.
• The global solid tumor cancer treatment market size is estimated to reach $532.42 billion by 2032.
• Besides Amgen, CytomX has been able to develop collaborations with other pharmaceutical companies like: Bristol-Myers Squibb, Moderna Therapeutics and Astellas.

CytomX Therapeutics, Inc. ( CTMX ) is gearing up to release its Q1 2024 earnings results post-market on May 8th of 2024. With this update on earnings, a good reason to keep an eye on this biotech is because it will also release phase 1a dose-escalation data. This will be regarding the use of CX-904 for the treatment of solid tumor types that express the EGFR mutation....

For further details see: